Please assess the completion status of the following clinical trial:

Trial Title: A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 15.0

Eligibility Criteria:
Inclusion Criteria:~Part 1, Part 2, Part 3 and Part 4~1. Male or female age 18- 64 years, inclusive~2. No relevant gastrointestinal symptoms~3. Able to abstain from alcohol for 72 hours prior to the Screening Visit; for 72 hours prior to and after the Cohort Treatment Day (Part 1, Part 2, and Part 3); for 72 hours prior to the Safety Visit (Part 2 and Part 3); and for 72 hours prior to Day 1 of the first Cohort Treatment Period through the Safety Visit (Part 4).~4. A female participant must have a negative pregnancy test at Screening and on Cohort Treatment Day -1 (Part 1, Part 2, and Part 3) or a negative pregnancy test at Screening and on Day -1 of each Cohort Treatment Period (Part 4), and must agree to continue acceptable birth control measures (example, abstinence, a stable hormonal contraceptive, double-barrier method, or vasectomy in partner) from the Screening Visit through the 28 ± 2 days. Follow Up ADA Blood Sampling Visit~5. A male participant must agree to use acceptable birth control measures (e.g., abstinence, latex condom, or vasectomy), or must have a female partner who will continue birth control measures (e.g., abstinence, a stable hormonal contraceptive, or double-barrier method) from the Screening Visit through the 28 ± 2 days Follow Up Anti-Drug Antibody Blood Sampling Visit~6. Able to read and understand English~7. Able to provide written informed consent~   Additional Inclusion Criteria for Part 1, Part 2, Part 3, and Part 4 Healthy Adult Volunteers~8. No use of over-the-counter or prescription medication, except for birth control medications for the duration of the study~9. No history of gastrointestinal diseases or disorders~10. No history of intolerance, sensitivity, or reactions to gluten or any other food or food ingredient~11. Able to maintain a gluten-free diet for 24 hours prior to the Cohort Treatment Day (Part 1, Part 2, and Part 3), or usually ingests meals three times a day (that is, breakfast, lunch, and dinner) and is able to continue doing so during each Cohort Treatment Period (Part 4)~    Additional Inclusion Criteria for Part 1 Participants with Celiac Disease~12. Documented history of Celiac Disease in medical records~13. Maintaining a gluten-free diet for ≥6 months~14. No use of over-the-counter or prescription medication, except for birth control medications and those allowed by the study doctor, for the duration of the study.~15. No history of gastrointestinal diseases or disorders, other than Celiac Disease~16. No history of intolerance, hypersensitivity, or reaction to any food or food ingredient~17. Able to continue a gluten-free diet for the duration of the study~Exclusion Criteria:~Part 1, Part 2, Part 3, and Part 4~1. Current symptoms or signs of illness~2. Chronic viral infection or immunodeficiency condition~3. Any female who is pregnant, planning to become pregnant during the study, or breast-feeding; any male who is planning to father a child during the study~4. Receipt (or planned receipt) of another investigational medication within 4 weeks prior to the Screening Visit through the duration of the study~5. Alcohol consumption greater than (\>) 5 drinks/week, alcohol consumption within 72 hours prior to any study visit (Part 1, Part 2, and Part 3), alcohol consumption within 72 hours prior to Day 1 of the first Cohort Treatment Period through the Safety Visit (Part 4), or a positive alcohol breathalyzer test at any study visit~6. History of illicit or recreational drug use within the three years prior to the Screening Visit, or a positive urine drug screen at any study visit~7. Use of tobacco or nicotine products, including smoking, smokeless tobacco, e-cigarettes, or nicotine replacement products within 12 months prior to the Screening Visit through the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Part 1, Cohort 1A-1 to 1D-1 Healthy Participants (Type: EXPERIMENTAL): A single dose of PvP001 placebo, PvP001 100 mg, PvP001 300 mg, or PvP001 900 mg will be administered in ascending order to healthy participants in Cohorts 1A-1, 1B-1, 1C-1, and 1D-1.
- Part 1, Cohort 1E-1 Healthy Participants (Type: EXPERIMENTAL): A single dose of the maximum feasible dose (MFD) of PvP002 will then be administered to healthy participants in Cohort 1E-1.
- Part 1, Cohort 1A-2 - 1D-2 Celiac Disease (CeD) (Type: EXPERIMENTAL): A single dose of PvP001 placebo, PvP001 100 mg, PvP001 300 mg, or PvP001 900 mg will be administered in ascending order to participants with CeD in Cohorts 1A-2, 1B-2, 1C-2, and 1D-2.
- Part 1, Cohort 1E-2 CeD (Type: EXPERIMENTAL): A single dose of the MFD of PvP002 will then be administered to participants with CeD in Cohort 1E-2.
- Part 2, Cohort 2A - Cohort 2C Healthy Participants (Type: EXPERIMENTAL): Participants will be blinded to the PvP001 dose (placebo or MTD of PvP001) and will also receive MTD of PvP001 following 7 days of PPI treatment.
- Part 2, Cohort 2D Healthy Participants (Type: EXPERIMENTAL): Participants will receive PvP001 placebo or MFD of PvP001.
- Part 2, Cohort 2E Healthy Participants (Type: EXPERIMENTAL): Participants will receive PvP002 placebo or MFD of PvP002.
- Part 2, Cohort 2F- Cohort 2H Healthy Participants (Type: EXPERIMENTAL): Participants will receive the PvP001 placebo and either 300 mg or 600 mg of PvP001.
- Part 2, Cohort 2I and Cohort 2J Healthy Participants (Type: EXPERIMENTAL): Participants will receive the PvP001 placebo and 900 mg of PvP001.
- Part 3, Cohorts 3A and 3B Healthy Participants (Type: EXPERIMENTAL): Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 with pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
- Part 3, Cohorts 3C and 3D Healthy Participants (Type: EXPERIMENTAL): Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
- Part 3, Cohorts 3E and 3F Healthy Participants (Type: EXPERIMENTAL): Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution after an approximately 50 milliliter (mL) portion of a standardized 1 gm gluten-containing study meal.
- Part 3, Cohorts 3G and 3H Healthy Participants (Type: EXPERIMENTAL): Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution before a standardized gluten-free study meal followed approximately 30 minutes later by a standardized 1 gm gluten-containing study meal.
- Part 4, Cohorts 4A and 4B Healthy Participants (Type: EXPERIMENTAL): Participants will receive multiple dose of PvP003 placebo and 600 mg of PvP003.
- Part 3, Cohorts 3I and 3J Healthy Participants (Type: EXPERIMENTAL): Participants will receive single dose of PvP003 placebo and 150 mg of PvP003 without pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete